Synthetic Biologics Inc SYN:NYSE American

Last Price$0.20AMEX Previous Close - Last Trade as of 8:00PM ET 6/28/22

Today's Change+0.005(2.51%)
Bid (Size)$0.20 (1)
Ask (Size)$0.21 (20)
Day Low / High$0.20 - 0.21
Volume711.3 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/28/2022

 

Synthetic Biologics Inc ( NYSE MKT LLC )

Price: $0.20
Change: +0.005 (2.51%)
Volume: 711.3 K
8:00PM ET 6/28/2022
 
 

Spero Therapeutics Inc ( NASDAQ )

Price: $0.77
Change: -0.17 (17.93%)
Volume: 1.5 K
4:00PM ET 6/28/2022
 
 

AcelRx Pharmaceuticals Inc ( NASDAQ )

Price: $0.22
Change: +0.01 (5.38%)
Volume: 56.5 K
4:00PM ET 6/28/2022
 
 

Cumberland Pharmaceuticals Inc ( NASDAQ )

Price: $2.04
Change: -0.02 (0.97%)
Volume: 1.8 K
4:00PM ET 6/28/2022
 
 

GlycoMimetics Inc ( NASDAQ )

Price: $0.61
Change: -0.01 (1.94%)
Volume: 80.0 K
4:00PM ET 6/28/2022
 

Read more news Recent News

Synthetic Biologics Names Frank Tufaro Chief Operating Officer
10:08AM ET 3/23/2022 MT Newswires

Synthetic Biologics (SYN) said Wednesday that Frank Tufaro has been named chief operating officer. Tufaro was COO of VCN Biosciences, which was acquired by...

Synthetic Biologics Closes Acquisition of VCN Biosciences
8:34AM ET 3/11/2022 MT Newswires

Synthetic Biologics (SYN) said Friday it has closed on its acquisition of clinical-stage biotech company VCN Biosciences. Synthetic said it paid $4.7...

Synthetic Biologics Says VCN Biosciences Secured FDA Orphan Drug Designation for Retinoblastoma Treatment
7:53AM ET 2/08/2022 MT Newswires

Synthetic Biologics (SYN) said Tuesday that the US Food and Drug Administration has granted orphan drug designation to VCN Biosciences' VCN-01 for the...

Synthetic Biologics Agrees to Buy VCN Biosciences
8:40AM ET 12/14/2021 MT Newswires

Synthetic Biologics (SYN) said Tuesday it has signed a definitive agreement to acquire VCN Biosciences, which is currently developing a potential treatment...

Company Profile

Business DescriptionSynthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD. View company web site for more details
Address9605 Medical Center Drive
Rockville, Maryland 20850
Phone+1.301.417.4364
Number of Employees13
Recent SEC Filing05/16/202210-Q
CEO, CFO, Treasurer & DirectorSteven A. Shallcross
Chief Operating OfficerFrank Tufaro
Senior Vice President-Research & DevelopmentMichael Kaleko
Director General-European RegionManel Cascalló

Company Highlights

Price Open$0.20
Previous Close$0.20
52 Week Range$0.18 - 0.64
Market Capitalization$31.7 M
Shares Outstanding158.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.12
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-22.60%

Analyst Ratings as of 11/16/2021

Buy
2
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset